Baxter Ventures identifies companies with promising technologies, products and/or therapies, and provides them with the capital and expertise needed to drive successful innovation. Baxter Ventures was created in 2011 by Baxter International Inc., which has an 80-year legacy of healthcare innovation and saving and sustaining lives worldwide.
| Company | Date | Round | Size | Participants |
| Ocular Therapeutix | 6/13 | Series E | $8.5M | 2 |
| Opsona | 4/13 | Series C | €33M | 8 |
| Zytoprotec | 1/13 | Series A | €2M | 1 |
| Naurex | 12/12 | Series B | $38M | 7 |
| Gliknik | 10/12 | Series B | $4.9M | 1 |
